Lactate dehydrogenase (LDH) as a predictor of left atrial remodeling in patients with sickle cell anemia

Fábio Galvão1, Felipe Soares Maia1, Mabel Rodrigues Rios1

  • 1Hematology and Transfusion Medicine Center, University of Campinas - UNICAMP, Campinas, SP, Brazil.

Insights

Lactate dehydrogenase (LDH) levels may predict left atrial enlargement in sickle cell anemia (SCA) patients. Elevated LDH (LDH/ULN > 1.2) significantly increases the risk of atrial remodeling, offering a simple marker beyond hemolysis.

Area of Science:

  • Cardiology
  • Hematology
  • Biomarker Research

Background:

  • Sickle cell anemia (SCA) causes cardiac complications, including left atrial enlargement, a risk factor for arrhythmias.
  • Lactate dehydrogenase (LDH) is a marker of hemolysis in SCA, but its role in atrial remodeling is understudied.

Purpose of the Study:

  • To investigate if LDH levels can predict left atrial enlargement in SCA patients.
  • To determine the association between elevated LDH and atrial remodeling in SCA.

Main Methods:

  • Retrospective cross-sectional study of 81 SCA patients.
  • Analysis of medical records, including echocardiographic data for left atrial volume index (LAVi).
  • Evaluation of LDH levels, expressed as multiples of the upper limit of normal (LDH/ULN).

Main Results:

  • 54% of patients had elevated LAVi; 64% had LDH/ULN > 1.0.
  • An LDH/ULN cut-off of 1.2 was identified to detect elevated LAVi.
  • LDH/ULN > 1.2 was associated with a 3.70-fold increased risk of elevated LAVi (p=0.012).

Conclusions:

  • LDH is associated with increased left atrial volume index in SCA patients.
  • LDH may serve as a simple, accessible marker for atrial remodeling in SCA, beyond its role in indicating hemolysis.